grant
Investigating Histone 3 Dopaminylation in Parkinson's Disease
Organization ICAHN SCHOOL OF MEDICINE AT MOUNT SINAILocation NEW YORK, UNITED STATESPosted 9 Sept 2024Deadline 8 Sept 2028
NIHUS FederalResearch GrantFY2025AD pathologyAD related dementiaADRDAffectAgeAgingAlanineAlzheimer's and related dementiasAlzheimer's dementia and related dementiaAlzheimer's dementia or related dementiaAlzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease or a related dementiaAlzheimer's disease or a related disorderAlzheimer's disease or related dementiaAlzheimer's disease pathologyAlzheimer's disease related dementiaAlzheimer's pathologyAmentiaAmmon HornAmygdalaAmygdaloid BodyAmygdaloid NucleusAmygdaloid structureAntimorphic mutationArchitectureAssayAutopsyBehaviorBehavioralBioassayBiochemicalBiological AssayBody TissuesBradykinesiaBrainBrain Nervous SystemBrain regionCell BodyCell Communication and SignalingCell DeathCell NucleusCell SignalingCell SurvivalCell ViabilityCellsCessation of lifeChIP SequencingChIP-seqChIPseqChemicalsChromatinChromatin StructureCognitionCognitiveCommon Rat StrainsComplexCornu AmmonisCorpus StriatumCorpus striatum structureCoupledDA NeuronDataDeathDegenerative Neurologic DisordersDementiaDiagnosisDisease ProgressionDominant NegativeDominant-Negative MutantDominant-Negative MutationDopamineDopamine neuronDopaminergic CellDrugsDysfunctionEmotionsEncephalonEngineering / ArchitectureEnvironmental FactorEnvironmental Risk FactorEnzyme GeneEnzymesEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEquilibriumFunctional disorderGene ExpressionGene TargetingGene TranscriptionGeneticGenetic TranscriptionGlnGlutamineGoalsHDAC AgentHDAC inhibitorHippocampusHistone Deacetylase InhibitorHistone deacetylase inhibitionHistonesHumanHydroxytyramineIncidenceInstitutionIntracellular Communication and SignalingL-GlutamineL-LysineLateralLearningLimbic SystemLinkLysineMAPseqMedialMediatingMedicalMedicationMemoryMethylationMiceMice MammalsMitochondriaModelingModern ManModificationMolecularMotorMovementMultiplexed Analysis of Projections by SequencingMurineMusMutateNerve DegenerationNerve Transmitter SubstancesNervous SystemNervous System Degenerative DiseasesNeural Degenerative DiseasesNeural degenerative DisordersNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Body SystemNeurologic Degenerative ConditionsNeurologic Organ SystemNeuron DegenerationNeurotransmittersNuclearNucleusOutputOxidative StressPD 1PD with dementiaPD-1PD1Paralysis AgitansParkinsonParkinson DiseaseParkinson Disease dementiaParkinson's DementiaParkinson's disease with dementiaPathologyPatientsPersonsPharmaceutical PreparationsPhenotypePhysiciansPhysiopathologyPlayPositionPositioning AttributePost-Translational Modification Protein/Amino Acid BiochemistryPost-Translational ModificationsPost-Translational Protein ModificationPost-Translational Protein ProcessingPosttranslational ModificationsPosttranslational Protein ProcessingPrefrontal CortexPrimary ParkinsonismProcessProtein ModificationProteinsQ LevoglutamideQ. LevoglutamideRNA ExpressionRNA SeqRNA sequencingRNAseqRatRats MammalsRattusRegulationResearchRest TremorRewardsRoleRotarod AssayRotarod MethodRotarod Performance TestRotarod TestSamplingScienceSeveritiesSignal TransductionSignal Transduction SystemsSignalingSiteSortingSourceStriate BodyStriatumStructureSubstantia NigraSubstantia nigra structureSymptomsTGase IITechniquesTestingTherapeuticTissuesTrainingTranscriptionTranslatingTransposaseTyrosine 3-MonooxygenaseTyrosine HydroxylaseUnited StatesVentral Tegmental AreaViralWorkagesamygdaloid nuclear complexattenuationbalancebalance functionbiological signal transductionbody movementchromatin immunoprecipitation coupled with sequencingchromatin immunoprecipitation followed by sequencingchromatin immunoprecipitation with sequencingchromatin immunoprecipitation-seqchromatin immunoprecipitation-sequencingcognitive functionconditioned feardata integrationdegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdementia in PDdementia in Parkinson diseasedisease modeldisorder modeldopaminergic neurondrug/agentenvironmental riskenzyme activityepigenetic biomarkerepigenetic markerepigenetic regulationepigeneticallyfear conditioninggenome scalegenome-widegenomewidehippocampalhistone demethylasehistone methylationhistone modificationin vivoinhibitorinnovateinnovationinnovativeinsightinterestmedical collegemedical schoolsmitochondrialmotor deficitmouse modelmurine modelnecrocytosisnecropsyneural degenerationneurodegenerationneurodegenerativeneurodegenerative illnessneurological degenerationneuronal degenerationneuroprotectionneuroprotectivenew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnovelnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetobject recognitionpars compactapathophysiologypostmortempostsynapticpreservationpreventpreventingprogrammed cell death 1programmed cell death protein 1programmed death 1protein homeostasisproteostasisschool of medicineskillssle2social rolestriatalsymptom treatmentsymptomatic treatmentsystemic lupus erythematosus susceptibility 2theoriestissue transglutaminasetissue-type transglutaminasetranscriptome sequencingtranscriptomic sequencingtranscriptomicstransglutaminase 2transglutaminase Ctransglutaminase IItransglutaminase TGM2treat symptomvectorvector controlventral tegmentum
Description preview
Summary/Abstract
Parkinson’s Disease (PD) is the second most common neurodegenerative disease affecting nearly one million
people in the United States, and up to 80% of PD patients eventually develop Parkinson’s Disease Dementia
(PDD), many with co-Alzheimer’s Disease pathology. PD is a neurodegenerative disease impacting the
dopaminergic cells in…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click